Gilead Sciences Inc. (NASDAQ:GILD) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on Gilead to $151 from $147 with an Overweight rating on ...

AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...

Keeley Wettan is succeeding Deborah Telman, who stepped down in November for reasons the company didn't explain.

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 19, ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable healthcare stocks to buy now. Gilead Sciences, Inc. (NASDAQ ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General ...

Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google.

Gilead will pay Repare $25m upfront, and up to an additional $5m upon completion of certain technology transfer activities.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Daniel O’Day and a group of Gilead employees visited with San Francisco Community Health Center staff last fall. Image courtesy of San Francisco Business Times. Originally published by SAN FRANCISCO ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthcare ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Mark Genovese, MD, has been appointed Senior Vice President, Inflammation, with responsibility for ...